Renal disease: A common and a silent killer

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue SUPPL. 1, 2008, Pages

  de Zeeuw, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FOSINOPRIL; HEMOGLOBIN; IRON; LIPID; LOSARTAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PRAVASTATIN; RECOMBINANT ERYTHROPOIETIN; RENIN;

AGE; ALBUMINURIA; ANEMIA; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE CLEARANCE; DEATH; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE FREE SURVIVAL; DRUG TARGETING; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; TREATMENT INDICATION; TREATMENT OUTCOME;

ALBUMINURIA; ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 46649111009     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0853     Document Type: Conference Paper

References (47)

1. Wilson PW et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837-1847
2. Conroy RM et al. (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 24: 987-1003
3. Hovens MM et al. (2005) Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: An update. Drugs 65: 433-445
4. De Zeeuw D et al. (2005) The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney Int Suppl: S25-S29
5. Smith GL et al. (2006) Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol 47: 1987-1996
6. Coresh J et al. (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 1-12
7. Pinto-Sietsma SJ et al. (2000) Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol 11: 1882-1888
8. Tapp RJ et al. (2004) Albuminuria is evident in the early stages of diabetes onset: Results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis 44: 792-798
9. Hallan H et al. (2003) Microalbuminuria in diabetic and hypertensive patients and the general population - consequences of various diagnostic criteria - the Nord-Trøndelag Health Study (HUNT). Scand J Urol Nephrol 37: 151-158
10. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39 (Suppl 1): S1-S266
11. Santoro A (2002) Anemia in renal insufficiency. Rev Clin Exp Hematol Suppl 1: 12-20
12. Iseki K et al. (2003) Haematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant 18: 899-905
13. Hall WD (1999) A rational approach to the treatment of hypertension in special populations. Am Fam Physician 60: 156-162
14. Jones CA et al. (1998) Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 32: 992-999
15. Yuyun MF et al. (2004) Microalbuminuria, cardiovascular risk factors and cardiovascular morbidity in a British population: The Epic-Norfolk Population-based Study. Eur J Cardiovasc Prev Rehabil 11: 207-213
16. Atkins RC et al. (2004) Prevalence of albuminuria in Australia: The AusDiab Kidney Study. Kidney Int Suppl: S22-S24
17. Hillege HL et al. (2004) Cystatin C, a novel marker for mortality in the general population: Data obtained from The PREVEND Study [abstract]. J Am Coll Cardiol 43: 519A
18. Filler G et al. (2005) Cystatin C as a marker of GFR - history, indications, and future research. Clin Biochem 38: 1-8
19. Go AS et al. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 1296-1305
20. Levey AS et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470
21. Shulman NB et al. (1989) Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13 (Suppl): 180-193
22. Hillege HL et al. (2003) Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: The CATS Randomized Trial. Eur Heart J 24: 412-420
23. Remuzzi G et al. (2004) Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 15: 3117-3125
24. Kannel WB et al. (1984) The prognostic significance of proteinuria: The Framingham Study. Am Heart J 108: 1347-1352
25. Hillege H L et al. (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782
26. Romundstad S et al. (2003) Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: A 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. Am J Kidney Dis 42: 466-473
27. Borch-Johnsen K et al. (1999) Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscier Thromb Vasv Biol 19: 1992-1997
28. Arnlov J et al. (2005) Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study. Circulation 112: 969-975
29. Wachtell K et al. (2003) Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Ann Intern Med 139: 901-906
30. De Zeeuw D et al. (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110: 921-927
31. Collins AJ (2003) The hemoglobin link to adverse outcomes. Advanced Studies in Medicine 3 (Suppl): S194-S197
32. Levin A et al. (1999) Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34: 125-134
33. McClellan WM et al. (2002) Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J Am Soc Nephrol 13: 1928-1936
34. Dahlöf B et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359 995-1003
35. Yusuf S et al. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153
36. Lewis EJ et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860
37. Parving H H et al.; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878
38. The GISEN Group (Gruppo Italiano Di Studi Epidemiologici In Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863
39. Brenner BM et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869
40. Mann JF et al. (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134: 629-636
41. Asselbergs FW et al. (2004) Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110: 2809-2816
42. Ibsen H et al. (2005) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 45: 198-202
43. Silverberg DS et al. (2003) The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18: 141-146
44. Besarab A et al. (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietin. N Engl J Med 339: 584-590
45. Singh AK et al. (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098
46. Drüeke TB et al. (2006) Normalization of hemoglobin levels in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084
47. Mix TC et al. (2005) Rationale-Trial to Reduce cardiovascular events with Aranesp™ Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 149: 408-413